Johnson & Johnson’s single coronavirus vaccine is much less effective against the Delta variant than against the original version of COVID-19, according to new study posted on the web Tuesday.
The study, which examined blood samples under laboratory conditions and has not yet been peer reviewed, recommends that anyone who received J&J
the vaccine may need a second shot as the variant continues to spread throughout the United States.
“The message we wanted to give was not that people should not get the J&J vaccine, but we hope it will be increased in the future with either a new dose of J&J or Pfizer or Moderna,” study leader Nathaniel Landau, NYU Grossman School of Medicine virologist, told The New York Times.
Earlier this month, Johnson & Johnson, based in New Jersey, released preliminary data showing the effectiveness of his vaccine initially against the Delta variant in India at least eight months after inoculation.
A vaccine similar to Johnson’s and Johnson’s vaccine was only effective at 33 percent against symptomatic disease caused by the Delta variant, and two doses at 60 percent were effective against symptomatic disease.
J&J spokesman Seema Kumar told the Times that the latest survey data “does not speak to the full nature of immunity”.
Last month, Dr. Rochelle Walensky was director of the Centers for Disease Control and Prevention (CDC) spoke to NBC on “Today” that “we have every reason to believe that J & J will work well against the Delta variant, as it has done against other variants in the United States so far.”
Walensky told lawmakers earlier Tuesday EurLex-2 en The Delta variant currently accounts for 83 percent of all US COVID-19 cases. At the same hearing, Dr Anthony Fauci, White House Medical Adviser, said researchers were still assessing whether repetitive techniques were needed to provide additional protection.
“We don’t want people to believe that when you talk about boosters, it means that vaccines are not effective,” Fauci said. “They’re very effective, we’re talking about its durability.”
Preliminary studies show that Moderna produced mRNA vaccines
are effective against the Delta variant and may provide protection for many years, provided that the virus does not mutate far from its original form.
The Delta variant has been blamed in recent weeks for the increase in cases, hospitalizations and deaths, although the number of all categories is still well below last winter’s peak and the vast majority of hospitalizations and deaths are among unvaccinated people.
Nevertheless, indoor health mandates have been reintroduced by Los Angeles and Las Vegas health officials, despite people’s vaccination status.